This study is testing a drug called sacituzumab tirumotecan (MK-2870) for treating certain stomach and intestine cancers. Some of these cancers have spread to other body parts, while others can't be removed with surgery. The study aims to find out how safe the drug is and if it helps shrink or eliminate the cancer when used alone or with chemotherapy.

To join, you must have one of these cancers: colorectal cancer that can't be removed or has spread, advanced pancreatic cancer, or bile duct cancer. You also must have had some cancer treatment before and recovered from its side effects. You can't join if you've had serious eye problems or certain lung diseases, or if you've had another cancer treatment recently.

• Study Length: Varies depending on individual response to treatment.
• Visits Needed: Regular visits for monitoring and treatment.
• Possible Risks: Side effects from the drug or chemotherapy.

Consider joining if you meet the conditions and are comfortable with the study requirements.